share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募資說明書
SEC announcement ·  04/12 14:13
Moomoo AI 已提取核心訊息
Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.
Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.
Allarity Therapeutics Inc.已於2024年4月12日提交了新的招股說明書補充文件，將其普通股的最高總髮行價從235萬美元提高到320萬美元。本文件修訂了先前於2023年11月29日發佈的招股說明書和2024年3月19日的招股說明書補充文件。根據市場發行銷售協議，該公司通過Ascendiant Capital Markets, LLC發行普通股。截至2024年2月28日，非關聯公司持有的Allarity普通股的市值約爲964萬美元，公開流通量爲1,126,573股。在過去的12個月中，該公司已經出售了價值2,167,957美元的普通股，根據美國證券交易委員會目前的指導方針，該公司最多可以再出售1,046,514美元的普通股。只要公衆持股量保持在7,500萬美元以下，出售股票的上限爲非關聯公司在任何12個月內持有的普通股總市值的三分之一。
Allarity Therapeutics Inc.已於2024年4月12日提交了新的招股說明書補充文件，將其普通股的最高總髮行價從235萬美元提高到320萬美元。本文件修訂了先前於2023年11月29日發佈的招股說明書和2024年3月19日的招股說明書補充文件。根據市場發行銷售協議，該公司通過Ascendiant Capital Markets, LLC發行普通股。截至2024年2月28日，非關聯公司持有的Allarity普通股的市值約爲964萬美元，公開流通量爲1,126,573股。在過去的12個月中，該公司已經出售了價值2,167,957美元的普通股，根據美國證券交易委員會目前的指導方針，該公司最多可以再出售1,046,514美元的普通股。只要公衆持股量保持在7,500萬美元以下，出售股票的上限爲非關聯公司在任何12個月內持有的普通股總市值的三分之一。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息